Pantoprazole
- Atc Codes:A02BC02
- CAS Codes:102625-70-7
- PHARMGKB ID:102625-70-7
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Azidex, Controloc, Gastroloc, Panprabene, Pantecta, Pantip, Pantobyk, Pantoloc, Pantoprazol, Pantozol, Somac, Zurcal; Belgium: Pantomed, Pantoprazol, Pantoprazole, Pantozol, Zurcale; Bulgaria: Pulcet; Cyprus: Pantodar, Pantozol; Czech Republic: Apo-Panto, Controloc, Nolpaza, Panogastin, Pantecta, Pantoloc, Pantoprazol, Pantoprazole, Pantozol, Pantul, Somac; Denmark: Pantoloc, Pantoprazol; Estonia: Controloc, Nolpaza, Panogastin, Pantoprazol, Pantoprazole, Pantul; Finland: Giasemin, Pantoprazol, Pantoprazole, Somac; France: Eupantol, Inipomp; Germany: Controloc, Eupantol, Fluxpan, Gastrozol, Nolpaza, Panogastin, Pantecta, Pantgrün, Panto, Pantodan, Pantoflux, Pantoham, Pantoloc, Pantomol, Pantopra, Pantoprazol, Pantorc, Pantoreddy, Pantorol, Pantosmiss, Pantotifi, Pantowald, Pantozol, Pantrolex; Greece: Controloc, Gastroprozal, Mediloc, Noxadif, Ozepran, Paderex, Pantium, Pantoprazol, Pantoprazole, Pantosec, Pezilpon, Praz-Up, Roxitrol, Ulcened, Ulceron, Verneg, Zurcazol; Hungary: Controloc, Gantrol, Gerprazol, Noacid, Nolpaza, Pafenon, Panogastin, Pantacid Flux, Pantoprazol, Pazolexa, Zeladrol, Zimpax; Ireland: Protium; Italy: Pantecta, Pantopan, Pantoprazolo, Pantorc, Peptazol; Luxembourg: Panto-Byk, Pantozol; Netherlands: Nolpaza, Pantecta, Pantoloc, Pantoprazol, Pantozol, Somac; Poland: Anesteloc, Contix, Contracid, Controloc, Gastrostad, Helopan, Noacid, Nolpaza, Panogastin, Panprazox, Panrazol, Pantecta, Pantoloc, Pantomed, Pantopraz, Pantoprazol, Pantoprazolum, Pantozol, Panzol, Pompec, Prasec, Ranloc, Somac; Portugal: Apton, Controloc, Ezzora, Pantecta, Pantoc, Pantoprazol; Romania: Azatol, Controloc, Dyspex, Nolpaza, Pacid, Pantecta, Pantexel, Pantoloc, Pantoprazolum, Pantosal, Seltraz, Somac, Zipantola; Slovakia: Controloc, Dyspex, Nolapaza, Panogastin, Pantecta, Pantoloc, Pantoprazol, Pantul, Somac; Slovenia: Acipan, Controloc, Nolpaza, Panrazol, Pantoprazol; Spain: Anagastra, Citrel, Panproton, Pantecta, Pantoprazol; Sweden: Caldazol, Controloc, Pantecta, Pantelke, Pantoloc, Pantonyco, Pantoprazol, Pantoprazole, Pantozol, Somac, Zapanzol, Zindazol; UK: Pantoprazole, Protium.
North America
Canada: Panto, Pantoloc, Pantoprazole, Tecta; USA: Pantoprazole, Protonix.
Latin America
Argentina: Gastromax, Pampar, Pangest, Pantocás, Pantop, Pantus, Peptazol, Sipar, Supracam; Brazil: Gastropan, Pantocal, Pantoprazol, Pantozol, Pantrat, Ziprol, Zurcal; Mexico: Panmicid, Pantoprazol, Pantozol, Peucetol, Prazolán, Supacid, Tecta, Tevozol, Zolpeptid, Zolpra, Zoltum-Asofarma, Zurcal.
Drug combinations
Pantoprazole, Amoxicillin, and Clarithromycin
Chemistry
Pantoprazole: C~16~H~15~F~2~N~3~O~4~S. Mw: 383.37. (1) 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-; (2) 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]benzimidazole. CAS-102625-70-7 (1991).
Pharmacologic Category
Antiulcer Agents and Acid Suppressants; Proton-pump Inhibitors. Substituted Benzimidazole. (ATC-Code: A02BC02).
Mechanism of action
Suppresses gastric acid secretion by inhibiting parietal cell H^+^/K^+^ ATP pump.
Therapeutic use
Treatment and maintenance of healing of erosive esophagitis associated with gastroesophageal reflux disease. Reduction in relapse rates of daytime and nighttime heartburn symptoms in gastroesophageal reflux disease. Hypersecretory disorders associated with Zollinger-Ellison syndrome, other gastrointestinal hypersecretory disorders, or other neoplastic disorders.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. There are no adequate, well-controlled studies in pregnant women. Use in pregnancy only if clearly needed. Not recommended during breast-feeding.
Unlabeled use
Peptic ulcer disease, active ulcer bleeding (parenteral formulation). Adjunct treatment with antibiotics for Helicobacter pylori eradication. Stress-ulcer prophylaxis in the critically-ill.
Contraindications
Hypersensitivity to pantoprazole, substituted benzamidazoles (e.g. esomeprazole, lansoprazole, omeprazole, rabeprazole), or any component of the formulation.
Warnings and precautions
Long-term pantoprazole therapy (especially in H. pylori-positive patients) caused atrophic gastritis. No occurrences of enterochromaffin-like cell carcinoids, dysplasia, or neoplasia reported in humans. Prolonged treatment (typically >3 years) may lead to vitamin B~12~ malabsorption and subsequent deficiency. Relief of symptoms does not preclude presence of gastric malignancy. Intravenous preparation contains edetate sodium (use caution in patients at risk for zinc deficiency if other edetate sodium-containing solutions are co-administered).